GlassScriptPhysician profile
Faranak Kamangar
NPI 1114293800
$18,074.85
in general payments reported to CMS, 2019-2025
18 companies · $693 in 2025
The $693 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.74 · 2020: $58.30 · 2021: $26.15 · 2022: $506 · 2023: $3,912 · 2024: $13K · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $2,775 · Travel and Lodging: $1,437 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,083.00 |
| Food and Beverage | $2,775.24 |
| Travel and Lodging | $1,437.22 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $9,224.86 | 2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $4,182.85 | 2019-2025 | Dupixent |
| Genzyme Corporation | $2,214.88 | 2024-2025 | |
| Ucb, INC. | $615.58 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $403.55 | 2019-2024 | |
| Dermavant Sciences, INC. | $283.78 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $221.07 | 2024-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $174.56 | 2022-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $114.94 | 2020-2025 | |
| Lilly USA, LLC | $113.27 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Eli Lilly and Company | $100.72 | 2024 | Ebglyss |
| Incyte Corporation | $75.37 | 2024-2025 | Opzelura |
| Amgen INC. | $72.42 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $70.41 | 2025 | Vtama, Nexplanon |
| Arcutis Biotherapeutics, INC. | $68.67 | 2024-2025 | Zoryve |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57.78 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.14 | 2019-2024 | Arazlo, Cabtreo, Jublia |
| Janssen Scientific Affairs, LLC | $40.00 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faranak Kamangar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.